After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
MRNA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Moderna Inc is $10.36B. A total of 8.01 million shares were traded on the day, compared to an average of 10.90M shares.
In the most recent transaction, Hussain Abbas sold 312 shares of MRNA for 28.00 per share on Jun 11 ’25. After the transaction, the Director now owns 580 company shares. In a previous transaction on Jun 11 ’25, Hussain Abbas bought 312 shares at 28.00 per share.
Among the insiders who bought shares, Bancel Stephane acquired of 160,314 shares on Mar 03 ’25 at a per-share price of $31.22. This resulted in the Chief Executive Officer holding 9,210,686 shares of MRNA after the transaction. In another insider transaction, SAGAN PAUL bought 31,620 shares at $31.76 per share on Mar 03 ’25. Company shares held by the Director now total 312,027.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, MRNA has a high of $138.07 and a low of $23.15.
As of this writing, MRNA has an earnings estimate of -$2.95 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$2.46 per share and a lower estimate of -$3.58.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MRNA’s latest balance sheet shows that the firm has $10.73B in Cash & Short Term Investments as of fiscal 2021. There were $916.00M in debt and $9.13B in liabilities at the time. Its Book Value Per Share was $26.01, while its Total Shareholder’s Equity was $14.14B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNA is Buy with a score of 2.96.
